

Published in final edited form as:

Curr Opin Infect Dis. 2013 October ; 26(5): 404–412. doi:10.1097/QCO.0b013e3283638104.

Brucellosis in low-income and middle-income countries

Matthew P. Rubach^a, Jo E.B. Halliday^b, Sarah Cleaveland^b, and John A. Crump^{a,c,d}

^aDivision of Infectious Diseases and International Health, Department of Medicine, Duke University, Durham, North Carolina, USA ^bInstitute of Biodiversity, Animal Health and Comparative Medicine, University of Glasgow, Glasgow, Scotland, UK ^cDuke Global Health Institute, Duke University, Durham, North Carolina, USA ^dCentre for International Health, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand

Abstract

Purpose of review—Human brucellosis is a neglected, underrecognized infection of widespread geographic distribution. It causes acute febrile illness and a potentially debilitating chronic infection in humans, and livestock infection has substantial socioeconomic impact. This review describes new information regarding the epidemiology of brucellosis in the developing world and advances in diagnosis and treatment.

Recent findings—The highest recorded incidence of human brucellosis occurs in the Middle East and Central Asia. Fever etiology studies demonstrate brucellosis as a cause of undifferentiated febrile illness in the developing world. Brucellosis is a rare cause of fever among returning travelers, but is more common among travelers returning from the Middle East and North Africa. Sensitive and specific rapid diagnostic tests appropriate for resource-limited settings have been validated. Randomized controlled trials demonstrate that optimal treatment for human brucellosis consists of doxycycline and an aminoglycoside. Decreasing the burden of human brucellosis requires control of animal brucellosis, but evidence to inform the design of control programs in the developing world is needed.

Summary—Brucellosis causes substantial morbidity in human and animal populations. While improvements in diagnostic options for resource-limited settings and stronger evidence for optimal therapy should enhance identification and treatment of human brucellosis, prevention of human disease through control in animals remains paramount.

Keywords

brucellosis; epidemiology; neglected diseases; zoonoses

INTRODUCTION

As a geographically widespread bacterial zoonotic infection that causes substantial morbidity in both human and livestock populations, brucellosis is a disease of global importance [1]. Brucellosis is caused by *Brucella* species, which are small, Gram-negative, unencapsulated coccobacilli first isolated by Bruce in 1887 [2]. Four species, *B. melitensis*,

© 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

Correspondence to John A. Crump, MB, ChB, DTM&H, McKinlay Professor of Global Health and Co-Director, Centre for International Health, PO Box 56, University of Otago, Dunedin 9054, New Zealand. Tel: +64 3 479 9460; fax: +64 3 479 7298; john.crump@otago.ac.nz.

Conflicts of interest

There are no conflicts of interest.

B. abortus, *B. suis*, and *B. canis*, are the main pathogens of human and livestock populations [3]. Similar to tuberculosis, brucellosis is a granulomatous disease that can affect any organ and requires long-term chemotherapeutics to achieve clinical cure. Infections with *Brucella* species are rarely fatal [4], but nonetheless can cause substantial morbidity in humans. Clinical presentation varies from an acute, nonspecific febrile illness to chronic, debilitating forms whose features may include osteoarticular involvement and neuropsychiatric abnormalities [4,5^{***}]. Although illnesses among returning travelers and among deployed military personnel underscore the relevance of brucellosis to practitioners in the developed world [6,7], the impacts of brucellosis are incurred largely in the developing world [8]. Fully capturing these impacts, however, is constrained by underrecognition on the part of health-care providers, limited availability of appropriate laboratory diagnostics, and healthcare seeking behaviors and access among those most at risk for brucellosis.

With the exception of infections acquired by laboratory personnel [9^{*}] and the potential use of *Brucella* as a bioterrorism agent [10], human infection is acquired through contact, ingestion, or inhalation of organisms from infected animals, principally cattle, goats, and sheep. Seroprevalence studies conducted throughout the developing world demonstrate that when one looks, *Brucella* infection is frequently found among sampled livestock populations [11–15,16^{***}].

In addition to transmitting the infection to humans, animal brucellosis impacts livestock productivity, which can have socioeconomic and indirect health effects on humans, especially vulnerable livestock-keeping populations in resource-limited settings that rely on livestock for food security and income [17,18]. The impacts of brucellosis in livestock include abortion and death as well as decreased milk production and reduced reproductive efficiency [13,19–21]. Control of brucellosis is accordingly a target for economic development set forth by the WHO and development agencies [22].

This review focuses on the epidemiology of brucellosis in low- and middle-income countries (LMICs). Recent data on brucellosis in returning travelers and advances in diagnosis, therapy, and control are also provided. For information on the immunology and pathogenesis of *Brucella* species infection, the reader is directed to other reviews [23–25].

EPIDEMIOLOGY OF HUMAN BRUCELLOSIS

Assessing the burden of disease due to human brucellosis – incidence, attributed disability, and case fatality rates – is challenging. Although prospective population-based surveillance of brucellosis has been conducted in several countries [26–30], none of these studies utilized active disease surveillance to estimate incidence and none reported mortality. Estimates of disability and mortality are also hindered by the proportion of cases presenting with febrile illness in brucellosis endemic areas that may be misdiagnosed [27], and by a limited understanding of the proportion of infections that progress to chronic disease. The majority of human brucellosis illnesses in endemic areas are attributed to *B. melitensis*, but disease due to other species may be underappreciated [31,32].

These limitations notwithstanding, it is well established that brucellosis is endemic throughout the Mediterranean rim and the Middle East, with incidence estimates more than 100 cases per 100 000 person-years in Iraq, Jordan, and Saudi Arabia [33–35]. Recent publications indicate that the incidence of brucellosis in central Asian countries, such as Kyrgyzstan and Azerbaijan, is similarly high [36,37].

The incidence data we present below draw largely from a systematic review of brucellosis, which provides a concise presentation of incidence and seroprevalence studies conducted throughout the world since 1990 [38^{***}]. Given the difficulties of establishing a laboratory-

confirmed case and the poor quality of data from sub-Saharan Africa, the only incidence data from sub-Saharan Africa included in this systematic review were from Chad [39]. From this study in Chad, an incidence of 35 cases per 100 000 person-years was derived from a seroprevalence of 3.8%, assuming a fixed proportion of clinical cases among seropositives (10%) and a fixed duration of seropositivity [38^{***}]. Robust disease incidence data are lacking in other regions of the world as well: whereas seroprevalence studies in China and Korea indicate brucellosis is endemic in some regions [40–42], we are unaware of incidence estimates in East Asia.

As for Oceania, a study conducted in the Polynesian islands of Wallis and Futuna demonstrated *B. suis* incidence of 19 cases per 100 000 person-years attributed to the high prevalence of pig husbandry in these island cultures [31].

In the Western Hemisphere, brucellosis incidence in Mexico has been estimated at 25.7 cases per 100 000 person-years, compared to 0.02 cases per 100 000 person-years in the United States [43]. Of note, the rates of brucellosis in United States counties along the US–Mexico border were substantially higher at 0.18 cases per 100 000 person-years compared to nonborder regions of the United States. In Argentina, one study found an incidence of 12.8 per 100 000 person-years [44]. Elsewhere in Latin America, brucellosis is thought to be endemic [1,8].

Although a broader survey of brucellosis incidence in LMICs is lacking, several cohort studies conducted in resource-limited settings demonstrate brucellosis as a cause of acute febrile illness. A meta-analysis of cohort studies that identified causative pathogens of community-acquired bloodstream infections in Africa found that *Brucella* species accounted for 275 (5%) of 5578 bloodstream infections [45,46]. All 275 cases of *Brucella* bacteremia were derived from a hospital-based fever etiology study in Egypt, where *Brucella* was the second most common cause of bloodstream infection, behind *Salmonella enterica* serotype Typhi [46]. A hospital-based fever etiology study in northern Tanzania found 16 (3.5%) of 455 febrile hospital admissions met the US Centers for Disease Control and Prevention (CDC) confirmed case definition for acute brucellosis [47,48^{*}]. Although relatively few cases were identified, laboratory-confirmed brucellosis was a more common cause of fever in this cohort than laboratory-confirmed malaria (3.5 vs. 1.8%), and none of the 16 patients received a clinical diagnosis of brucellosis. A fever etiology study in northwestern Ethiopia also found a low proportion of febrile disease attributed to brucellosis, 17 (2.6%) of 653 patients [49]. A study in the Ecuadorian Amazon basin identified brucellosis as the cause of undifferentiated febrile illness in four (1.3%) of 304 patients [50]. In a systematic review of the etiology of fever of unknown origin (FUO) in children, 97 (10%) of 989 cases from the developing world were attributed to brucellosis, the most common infectious cause [51]. A prospective, single-center FUO study in Egyptian adults similarly found brucellosis to be the most common infectious cause [52].

Surveillance studies of ill travelers returning from developing countries indicate that brucellosis was a rare cause of illness [53–56]. However, among travelers returning from the Middle East and North Africa, brucellosis was the third most common cause of febrile illness [57^{*}]. Compared to nonexpatriate returning travelers, returning expatriates had an overall small, but significantly higher prevalence of brucellosis (2 per 1000 persons vs. 0.4 per 1000 persons, $P < 0.01$) [6]. Brucellosis was first described in the context of recurrent fevers among British soldiers in Malta [2,58], and it remains an important consideration in the evaluation of ill military personnel deployed overseas [7].

As in high-income settings, the risk factors for human brucellosis in LMICs include ingestion of unpasteurized dairy products and exposure through direct contact with infected

animal body fluids or tissues, especially the placenta from aborted animals [59–63]. This is reflected in a higher risk of disease in marginalized livestock-keeping communities, as well as veterinary and abattoir workers. However, there is also evidence from cities in sub-Saharan Africa that brucellosis is a cause of febrile illness in urban settings, linked to the sale and distribution of contaminated raw milk [48*,64,65].

The case fatality rate for brucellosis has not been derived from prospective surveillance. However, data from retrospective cohorts would indicate that death from brucellosis occurs in less than 1% of cases [1,4]. Recently proposed disability weights estimate acute brucellosis at a level comparable to acute malaria, 0.190, and the estimated disability weight for chronic, localized brucellosis was 0.150, rendered similar to osteoarticular disease, a common form of focal brucellosis [5**].

CLINICAL MANIFESTATIONS

Fever in brucellosis can be acute and associated with rigors or it can be chronic, low-grade, and relapsing. A systematic review gives a comprehensive assessment of the clinical manifestations of human brucellosis [5**]. Arthralgia, myalgia, and back pain occur in 65, 47, and 45% of cases, respectively. Hepatomegaly, splenomegaly, and overt arthritis are seen in approximately 25%, respiratory involvement in 20%, and vertebral spondylitis in 12% of cases. Epididymo-orchitis is present in 10% of cases in men. Endocarditis and neuropsychiatric complications occur in 1 and 4% of cases, respectively. The most common neuropsychiatric manifestation is meningoencephalitis, often chronic, but other sequelae include cranial nerve deficits, seizure, and psychological disturbance. Of note, this systematic review did not find high-quality studies from sub-Saharan Africa, Latin America, or Asia to include in their meta-analysis. Whether disease manifestations might vary by region or by infecting *Brucella* species merits further investigation. For instance, whereas hematologic abnormalities such as anemia and leukopenia are common in Mediterranean populations, thrombocytopenia is fairly uncommon [66,67]; in contrast, over 40% of the brucellosis cases in the northern Tanzania fever cohort had thrombocytopenia [48*]. Compared to *B. melitensis* infections, *B. suis* appears to cause marked elevation in alanine aminotransferase [31] and *B. abortus* is thought to cause more mild disease [68]; but in general, data are limited regarding species-specific manifestations.

In Mediterranean populations, *Brucella* is a common cause of vertebral osteomyelitis, accounting for up to a quarter of all cases [69]. To distinguish *Brucella* vertebral osteomyelitis cases from *Mycobacterium tuberculosis* infection, clinicians must undertake thorough evaluations, including serologic testing for *Brucella* antibodies as well as sampling of the involved tissue when feasible. Radiographic features can help distinguish between these two granulomatous spine infections: intervertebral disc spaces are not typically involved in tubercular spine infections, whereas they are often narrowed in brucellar spine infections [70]. Conversely, the following findings are thought to be rare in brucellar cases: involvement of the posterior spinal elements and vertebral collapse (both findings are more suggestive of tubercular cases) as well as epidural abscess formation (more suggestive of pyogenic or tubercular spondylodiscitis) [70,71].

Studies of pregnancy loss show that although there is no significant linkage between prior brucellosis exposure and abortion [72], women diagnosed with acute or chronic brucellosis during pregnancy had a high prevalence of abortion, ranging from 14 to 43% [73].

CLINICAL DIAGNOSIS AND DIAGNOSTIC ADVANCES

Although brucellosis can present with signs and symptoms that may raise clinical suspicion, acute brucellosis is often difficult to distinguish from other febrile conditions, and delayed

diagnosis is common. In one large series from a high-income setting, over a third of patients had symptoms for 1–3 months prior to diagnosis [74]. The same study found that a delay in diagnosis of more than 30 days was associated with increased risk of developing complicated focal forms of brucellosis, and patients with osteoarticular involvement often experience 6 months of symptoms prior to receiving the correct diagnosis [75]. In low-income settings in Tanzania, only 22% of patients with probable brucellosis reported to health facilities within 1 month, and 20% presented after 1 year of symptoms [76].

The US CDC confirmed case definition for human brucellosis requires a clinically compatible syndrome and either isolation of *Brucella* species from culture of clinical specimens or at least a four-fold rise in *Brucella* antibody titer [measured by standard agglutination test (SAT) or micro-agglutination test (MAT)] between acute and convalescent sera obtained at least 14 days apart [47]. The US CDC probable case definition requires a clinically compatible syndrome and one of the following: a single SAT or MAT antibody titer at least 1 : 160; detection by PCR of *Brucella* DNA in a clinical specimen; or an epidemiologic link to a confirmed case. Neither the US CDC nor WHO has a specific definition for chronic brucellosis [47,77]. Most experts would propose more than 12 months of symptoms [1] and a single SAT or MAT titer at least 1 : 160 [77], though false-negative SAT or MAT results do occur in chronic brucellosis [78].

Conventional blood culture methods using biphasic Ruiz-Castaneda bottles require 6 weeks of incubation and the diagnostic yield varies from 40–90% in acute cases to 5–20% in chronic cases [79]. Automated blood culture systems have a 5–10% higher recovery rate than biphasic methods, and the majority of isolates are recovered within 1 week [79]. Bone marrow culture, considered the gold standard, has 15–20% higher yield than peripheral blood culture [78,79]. Given the variable yield of culture, especially in subacute and chronic disease, serologic testing is often relied upon when brucellosis is suspected.

The Rose Bengal agglutination test has a sensitivity more than 90% in most studies [80–82]. It has served as a mainstay for screening in both human and animal populations, but it lacks specificity, so confirmatory testing of positive samples is required [82]. SAT and MAT remain the reference standards for serologic confirmation of brucellosis with a specificity of 99% for acute disease in endemic settings [82,83]. Commercial ELISAs for *Brucella* IgG and IgM are available, and studies indicate they are sensitive [84]. However, due to relatively low specificity of some ELISA tests, the US CDC recommends that they should not be used to confirm brucellosis cases [85]. The antigen cross-reactivity between *Brucella* species precludes speciation by serology. The exception is *B. canis*, which does not share cross-reacting antigens with other *Brucella* species [78], and therefore, when suspected, one must select serologic testing specific for *B. canis* antigens.

In recent years, considerable effort has been mobilized toward the development of rapid, reliable field diagnostic assays [86] and molecular diagnostic approaches. Lateral flow assays do not require extensive laboratory infrastructure or technical expertise, and compared to the standard of SAT and/or culture, the sensitivity and specificity were 92–95 and 97%, respectively, in endemic settings [87,88]. Rapid latex agglutination tests can also be useful in areas with limited laboratory capacity, and one study using culture-confirmed cases and negative controls demonstrated a sensitivity of 89% and a specificity of 98% [89]. PCR was effectively employed to rapidly detect *Brucella* DNA in the blood of six suspected cases which all subsequently met confirmed case definitions [90], and multiplex assays can expedite the confirmation and speciation of *Brucella* isolated by culture [91,92]. A real-time PCR assay that rapidly and accurately distinguishes *Brucella* from *M. tuberculosis* in body fluid and tissue specimens holds promise for clinical use [93].

TREATMENT

Tetracyclines and a parenteral aminoglycoside or tetracyclines and rifampin are the regimens historically recommended by the WHO for treatment of human brucellosis [94^{***}]. Combination antibacterial therapy is imperative as single-drug therapy is associated with 2.5-fold increased risk of treatment failure [95]. In the past 10 years, several clinical trials comparing regimens for the treatment of brucellosis have been conducted [96–100], and two systematic reviews of therapy for brucellosis were published in 2012 [94^{***},101]. These studies consistently demonstrate the following principles for brucellosis therapy: 6 weeks of doxycycline with 7 days of gentamicin is as effective as 6 weeks of doxycycline with 14 days of streptomycin [96,100,101]; doxycycline along with an aminoglycoside appears to be superior to doxycycline with rifampin, and has lower rates of minor adverse events than doxycycline–rifampin regimens [94^{***},97]; rifampin along with a fluoroquinolone is less efficacious, but remains a viable third-line regimen [95,97]. Recommended agents to treat children include rifampin, amino-glycosides, and trimethoprim–sulfamethoxazole (Table 1) [1].

Based on meta-analyses of therapeutic trials, treatment failure or relapse is 5–7% for doxycycline–streptomycin regimens and 11–17% for doxycycline–rifampin [94^{***},101]. In observational studies, a higher proportion of relapse has been noted among patients with osteoarticular disease [4], and some experts recommend a treatment duration of 8–12 weeks for vertebral spondylodiscitis [1,102].

Given the rates of treatment failure or relapse and the geographic and antimicrobial regimen overlap that exists between brucellosis and tuberculosis, antimicrobial resistance of *Brucella* species has received attention in recent years. Both in-vitro susceptibility studies [103,104,105^{*}] and molecular detection methods of resistance [106,107] performed on clinical isolates of *B. melitensis* have yet to demonstrate rifampin resistance and the minimum inhibitory concentrations for other agents remain reassuringly low.

CONTROL AND PREVENTION

Brucellosis control and prevention strategies aim to minimize disease impacts and reduce animal-to-human disease transmission [1,108].

Human vaccine against brucellosis has been employed in the past, but vaccines are not widely available and concerns exist about their safety [109]. Animal vaccination campaigns followed by compulsory test-and-slaughter programs have contributed to the elimination of *B. abortus* and *B. melitensis* in some developed countries, but successful campaigns have all been expensive, long, and difficult to implement [110^{***}]. For these reasons, elimination is likely infeasible in endemic LMICs [8,111]. In such settings, the implementation of effective test-and-slaughter policies is limited by the lack of resources to compensate farmers whose animals are slaughtered [111–113]. Test-and-slaughter policies can also paradoxically contribute to the spread of infection, when identified seropositive animals are sold instead of slaughtered [114].

Vaccination of animal populations can reduce animal infection prevalence and human disease risk. The most widely used vaccines, both live-attenuated, are *B. melitensis* Rev1 (Rev1), which is used in sheep and goats, and *B. abortus* S19 (S19), which is used in cattle. Both induce good protection but both can be abortifacient if administered during pregnancy; both also interfere with serological diagnostic testing, which is required when vaccination is combined with test-and-slaughter programs [111]. A 5-year pre- and postvaccine assessment of the Rev1 vaccine among small ruminant animals in Tajikistan showed an 80% reduction in herd prevalence in areas with high vaccine uptake, 40% reduction in prevalence in areas

with low coverage, and no changes in the areas where no vaccination was undertaken [115^{***}]. Cost-effectiveness modeling of a 10-year mass-vaccination campaign using Rev1 vaccine for small ruminants and S19 vaccine for cattle in Mongolia estimated that a 52% reduction in transmission between animals could be achieved and a total of 49 027 disability-adjusted life years could be averted. In a scenario wherein costs were shared between public health and livestock sectors, this study indicates that livestock vaccination would be cost-effective and result in net economic benefit [17].

Although milk pasteurization is a more downstream control strategy, it can reduce *Brucella* transmission to humans. A study of bulk milk samples in Kampala, Uganda modeled a 47% risk reduction in human brucellosis if pasteurization centers could be incorporated into the urban milk production chain [65]. Infection risk among persons in frequent contact with potentially infected animals can also be reduced through personal hygiene measures and adoption of safe working practices, including use of protective clothing, disinfection of protective clothing, and disinfection of potentially infected implements and premises [1]. Such measures may be untenable in LMICs due to resource limitations and animal husbandry cultural traditions.

In resource-limited settings, the control of brucellosis in animal populations can achieve substantial health and economic benefits in both animal and human sectors [17,115^{***}]. Further studies to describe the reservoir dynamics of brucellosis in endemic countries and evaluate the cost-effectiveness of control efforts are needed to inform policymakers at all levels [110^{**},116].

CONCLUSION

Brucellosis is widespread in LMICs, most prominently in the Mediterranean rim, Middle East and Central Asia, with accurate assessments largely lacking in other regions. Brucellosis is a cause of nonspecific febrile illness in LMICs and a rare cause of febrile illness among returning travelers. An appropriate index of suspicion based on risk factors and local prevalence is required, as undifferentiated fever syndromes due to brucellosis have the potential to evolve into chronic, debilitating focal forms, and the treatment for acute brucellosis is unique compared to empiric regimens for other causes of fever in LMICs. Although mortality is low, treatment failure or relapse is not infrequent despite low levels of antimicrobial resistance. Control of brucellosis in livestock is the best strategy for decreasing the disease burden in humans, but more research on the cost-effectiveness of control strategies in LMICs is required. As much of our knowledge on the epidemiology and clinical manifestations of brucellosis is derived from the populations of the Mediterranean rim, further research is needed on the incidence, causative species, risk factors, and manifestations of brucellosis in other regions of the world.

Acknowledgments

M.P.R. receives funding support from the Fogarty Global Health Fellowship through the Fogarty International Center at the US National Institutes of Health (R25TW009343). J.E.B.H. and S.C. both receive funding support from the United Kingdom Biotechnology and Biomedical Sciences Research Council (BB/J010367/1). S.C. also receives funding support from the United Kingdom Biotechnology and Biomedical Sciences Research Council (BB/H009302/1 and BB/H00935/1), the World Health Organization (HQNTD1206296), and the Wellcome Trust (096400/Z/11/Z). J.A.C. currently receives funding from the Fogarty International Center at the US National Institutes of Health (R01TW009237).

REFERENCES AND RECOMMENDED READING

Papers of particular interest, published within the annual period of review, have been highlighted as:

- of special interest
- of outstanding interest

Additional references related to this topic can also be found in the Current World Literature section in this issue (pp. 484–485).

1. Corbel, MJ. Brucellosis in humans and animals. Geneva: WHO; 2006. <http://www.who.int/csr/resources/publications/Brucellosis.pdf> [Accessed 28 March 2013]
2. Bruce D. Note on the discovery of a micro-organism in Malta fever. *Practitioner*. 1887; 39:161–170.
3. Pappas G. The changing *Brucella* ecology: novel reservoirs, new threats. *Int J Antimicrob Agents*. 2010; 36 (Suppl 1):S8–S11. [PubMed: 20696557]
4. Buzgan T, Karahocagil MK, Irmak H, et al. Clinical manifestations and complications in 1028 cases of brucellosis: a retrospective evaluation and review of the literature. *Int J Infect Dis*. 2010; 14:e469–e478. [PubMed: 19910232]
- 5▪. Dean AS, Crump L, Greter H, et al. Clinical manifestations of human brucellosis: a systematic review and meta-analysis. *PLoS Negl Trop Dis*. 2012; 6:e1929. This meta-analysis gives a comprehensive summation of clinical manifestations of human brucellosis, and the disability weights for brucellosis presented in this study represent an important step toward estimating the burden of disease due to brucellosis. [PubMed: 23236528]
6. Lim PL, Han P, Chen LH, et al. Expatriates ill after travel: results from the Geosentinel Surveillance Network. *BMC Infect Dis*. 2012; 12:386. [PubMed: 23273048]
7. Bechtol D, Carpenter LR, Mosites E, et al. *Brucella melitensis* infection following military duty in Iraq. *Zoonoses Public Health*. 2011; 58:489–492. [PubMed: 21824352]
8. Pappas G, Papadimitriou P, Akritidis N, et al. The new global map of human brucellosis. *Lancet Infect Dis*. 2006; 6:91–99. [PubMed: 16439329]
- 9▪. Sayin-Kutlu S, Kutlu M, Ergonul O, et al. Laboratory-acquired brucellosis in Turkey. *J Hosp Infect*. 2012; 80:326–330. Laboratory-acquired brucellosis is not uncommon and poses challenges in *Brucella* endemic areas, which often are lacking the adequate infrastructure to maintain appropriate biosafety. [PubMed: 22365915]
10. Pappas G, Panagopoulou P, Christou L, Akritidis N. *Brucella* as a biological weapon. *Cell Mol Life Sci*. 2006; 63:2229–2236. [PubMed: 16964579]
11. Hegazy YM, Moawad A, Osman S, et al. Ruminant brucellosis in the Kafr El Sheikh Governorate of the Nile Delta, Egypt: prevalence of a neglected zoonosis. *PLoS Negl Trop Dis*. 2011; 5:e944. [PubMed: 21264355]
12. Borba MR, Stevenson MA, Goncalves VS, et al. Prevalence and risk-mapping of bovine brucellosis in Maranhao State, Brazil. *Prev Vet Med*. 2013; 110:169–176. [PubMed: 23218657]
13. Megersa B, Biffa D, Abunna F, et al. Seroprevalence of brucellosis and its contribution to abortion in cattle, camel, and goat kept under pastoral management in Borana, Ethiopia. *Trop Anim Health Prod*. 2011; 43:651–656. [PubMed: 21088890]
14. Gomo C, de Garine-Wichatitsky M, Caron A, Pfukenyi DM. Survey of brucellosis at the wildlife-livestock interface on the Zimbabwean side of the Great Limpopo Transfrontier Conservation Area. *Trop Anim Health Prod*. 2012; 44:77–85. [PubMed: 21643664]
15. Kashiwazaki Y, Ecewu E, Imaligat JO, et al. Epidemiology of bovine brucellosis by a combination of rose bengal test and indirect ELISA in the five districts of Uganda. *J Vet Med Sci*. 2012; 74:1417–1422. [PubMed: 22785123]
- 16▪. Asmare K, Megersa B, Denbarga Y, et al. A study on seroprevalence of caprine brucellosis under three livestock production systems in southern and central Ethiopia. *Trop Anim Health Prod*. 2013; 45:555–560. This cross-sectional seroprevalence study in goats demonstrates that prevalence at the individual animal and the individual herd level differs significantly between sedentary, agro-pastoralist, and pastoralist production systems, with pastoralists herds being significantly more likely to have seropositive goats. [PubMed: 22961233]
17. Roth F, Zinsstag J, Orkhon D, et al. Human health benefits from livestock vaccination for brucellosis: case study. *Bull World Health Organ*. 2003; 81:867–876. [PubMed: 14997239]

18. Perry BD, Grace D, Sones K. Current drivers and future directions of global livestock disease dynamics. *Proc Natl Acad Sci U S A*. 2011 Epub ahead of print.
19. Bernues A, Manrique E, Maza MT. Economic evaluation of bovine brucellosis and tuberculosis eradication programmes in a mountain area of Spain. *Prev Vet Med*. 1997; 30:137–149. [PubMed: 9234417]
20. Haileselassie M, Kalayou S, Kyule M, et al. Effect of *Brucella* infection on reproduction conditions of female breeding cattle and its public health significance in Western Tigray, northern Ethiopia. *Vet Med Int*. 2011; 2011:354943. [PubMed: 21822466]
21. Olsen S, Tatum F. Bovine brucellosis. *Vet Clin North Am Food Anim Pract*. 2010; 26:15–27. [PubMed: 20117540]
22. World Health Organization. The control of neglected zoonotic diseases: a route to poverty alleviation. Reports of a joint WHO/DIFD-Animal Health Programme meeting with the participation of FAO and OIE; Geneva. 20–21 September 2005; Geneva: WHO; 2006. http://www.who.int/zoonoses/Report_Sept06.pdf
23. Franco MP, Mulder M, Gilman RH, Smits HL. Human brucellosis. *Lancet Infect Dis*. 2007; 7:775–786. [PubMed: 18045560]
24. Pappas G, Akritidis N, Bosilkovski M, Tsianos E. Brucellosis. *N Engl J Med*. 2005; 352:2325–2336. [PubMed: 15930423]
25. Cannella AP, Tsolis RM, Liang L, et al. Antigen-specific acquired immunity in human brucellosis: implications for diagnosis, prognosis, and vaccine development. *Front Cell Infect Microbiol*. 2012; 2:1. [PubMed: 22919593]
26. Jennings GJ, Hajjeh RA, Girgis FY, et al. Brucellosis as a cause of acute febrile illness in Egypt. *Trans R Soc Trop Med Hyg*. 2007; 101:707–713. [PubMed: 17442354]
27. Crump JA, Youssef FG, Luby SP, et al. Estimating the incidence of typhoid fever and other febrile illnesses in developing countries. *Emerg Infect Dis*. 2003; 9:539–544. [PubMed: 12737736]
28. Gargouri N, Walke H, Belbeisi A, et al. Estimated burden of human *Salmonella*, *Shigella*, and *Brucella* infections in Jordan, 2003–2004. *Foodborne Pathog Dis*. 2009; 6:481–486. [PubMed: 19415972]
29. Minas M, Minas A, Gourgulianis K, Stournara A. Epidemiological and clinical aspects of human brucellosis in Central Greece. *Jpn J Infect Dis*. 2007; 60:362–366. [PubMed: 18032835]
30. Avdikou I, Maipa V, Alamanos Y. Epidemiology of human brucellosis in a defined area of Northwestern Greece. *Epidemiol Infect*. 2005; 133:905–910. [PubMed: 16181512]
31. Guerrier G, Daronat JM, Morisse L, et al. Epidemiological and clinical aspects of human *Brucella suis* infection in Polynesia. *Epidemiol Infect*. 2011; 139:1621–1625. [PubMed: 21733252]
32. Lucero NE, Corazza R, Almuzara MN, et al. Human *Brucella canis* outbreak linked to infection in dogs. *Epidemiol Infect*. 2010; 138:280–285. [PubMed: 19653929]
33. Al-Tawfiq JA, Abukhamsin A. A 24-year study of the epidemiology of human brucellosis in a health-care system in Eastern Saudi Arabia. *J Infect Public Health*. 2009; 2:81–85. [PubMed: 20701865]
34. Abu Shaqra QM. Epidemiological aspects of brucellosis in Jordan. *Eur J Epidemiol*. 2000; 16:581–584. [PubMed: 11049102]
35. Yacoub AA, Bakr S, Hameed AM, et al. Seroepidemiology of selected zoonotic infections in Basra region of Iraq. *East Mediterr Health J*. 2006; 12:112–118. [PubMed: 17037228]
36. Bonfoh B, Kasymbekov J, Durr S, et al. Representative seroprevalences of brucellosis in humans and livestock in Kyrgyzstan. *Ecohealth*. 2012; 9:132–138. [PubMed: 22143553]
37. Abdullayev R, Kracalik I, Ismayilova R, et al. Analyzing the spatial and temporal distribution of human brucellosis in Azerbaijan (1995–2009) using spatial and spatio-temporal statistics. *BMC Infect Dis*. 2012; 12:185. [PubMed: 22873196]
38. Dean AS, Crump L, Greter H, et al. Global burden of human brucellosis: a systematic review of disease frequency. *PLoS Negl Trop Dis*. 2012; 6:e1865. This systematic review used rigorous inclusion criteria, resulting in a valuable repository of epidemiologic studies of brucellosis since 1990. Their review highlights the limited data that exist on the incidence of brucellosis, but available studies show that brucellosis incidence can vary widely between regions within endemic countries. [PubMed: 23145195]

39. Schelling E, Diguimbaye C, Daoud S, et al. Brucellosis and Q-fever seroprevalences of nomadic pastoralists and their livestock in Chad. *Prev Vet Med.* 2003; 61:279–293. [PubMed: 14623412]
40. Wang Y, Zhang W, Ke Y, et al. Human brucellosis, a heterogeneously distributed, delayed, and misdiagnosed disease in China. *Clin Infect Dis.* 2013; 56:750–751. [PubMed: 23175566]
41. Zhang WY, Guo WD, Sun SH, et al. Human brucellosis, inner Mongolia, China. *Emerg Infect Dis.* 2010; 16:2001–2003. [PubMed: 21122244]
42. Deqiu S, Donglou X, Jiming Y. Epidemiology and control of brucellosis in China. *Vet Microbiol.* 2002; 90:165–182. [PubMed: 12414142]
43. Doyle TJ, Bryan RT. Infectious disease morbidity in the US region bordering Mexico, 1990–1998. *J Infect Dis.* 2000; 182:1503–1510. [PubMed: 11010841]
44. Marder GSF, Czenik GE, Duran G. Seroprevalencia de brucelosis en hemodonantes del Banco de Sangre de Corrientes, Argentina [Seroprevalence of brucellosis in blood donors from Banco de Sangre de Corrientes, Argentina]. *Revista Veterinaria.* 2005; 16:61–64.
45. Reddy EA, Shaw AV, Crump JA. Community-acquired bloodstream infections in Africa: a systematic review and meta-analysis. *Lancet Infect Dis.* 2010; 10:417–432. [PubMed: 20510282]
46. Afifi S, Earhart K, Azab MA, et al. Hospital-based surveillance for acute febrile illness in Egypt: a focus on community-acquired bloodstream infections. *Am J Trop Med Hyg.* 2005; 73:392–399. [PubMed: 16103611]
47. Centers for Disease Control and Prevention. 2012 Case Definitions: Nationally Notifiable Diseases and Conditions. Atlanta: CDC; 2012. http://www.cdc.gov/nndss/document/2012_Case%20Definitions.pdf [Accessed 27 December 2012]
48. Bouley AJ, Biggs HM, Stoddard RA, et al. Brucellosis among hospitalized febrile patients in northern Tanzania. *Am J Trop Med Hyg.* 2012; 87:1105–1111. A prospective fever etiology cohort study that demonstrates brucellosis is an underrecognized cause of severe febrile illness in northern Tanzania. [PubMed: 23091197]
49. Anmut A, Mekonnen Y, Shimelis D, Ephraim E. Febrile illnesses of different etiology among outpatients in four health centers in Northwestern Ethiopia. *Jpn J Infect Dis.* 2009; 62:107–110. [PubMed: 19305049]
50. Manock SR, Jacobsen KH, de Bravo NB, et al. Etiology of acute undifferentiated febrile illness in the Amazon basin of Ecuador. *Am J Trop Med Hyg.* 2009; 81:146–151. [PubMed: 19556580]
51. Chow A, Robinson JL. Fever of unknown origin in children: a systematic review. *World J Pediatr.* 2011; 7:5–10. [PubMed: 21191771]
52. Ali-Eldin FA, Abdelhakam SM, Ali-Eldin ZA. Clinical spectrum of fever of unknown origin among adult Egyptian patients admitted to Ain Shams University Hospitals: a hospital based study. *J Egypt Soc Parasitol.* 2011; 41:379–386. [PubMed: 21980776]
53. Flores-Figueroa J, Okhuysen PC, von Sonnenburg F, et al. Patterns of illness in travelers visiting Mexico and Central America: the GeoSentinel experience. *Clin Infect Dis.* 2011; 53:523–531. [PubMed: 21832261]
54. Field V, Gautret P, Schlagenhauf P, et al. Travel and migration associated infectious diseases morbidity in Europe, 2008. *BMC Infect Dis.* 2010; 10:330. [PubMed: 21083874]
55. Rapp C, Aoun O, Ficko C, et al. Travel-related cerebromeningeal infections: the 8-year experience of a French Infectious Diseases Unit. *J Travel Med.* 2010; 17:1–7. [PubMed: 20074095]
56. Freedman DO, Weld LH, Kozarsky PE, et al. Spectrum of disease and relation to place of exposure among ill returned travelers. *N Engl J Med.* 2006; 354:119–130. [PubMed: 16407507]
57. Leder K, Torresi J, Libman MD, et al. GeoSentinel surveillance of illness in returned travelers, 2007–2011. *Ann Intern Med.* 2013; 158:456–468. A recent installment from the GeoSentinel network, which showed that brucellosis was the third most common cause of nonspecific febrile illnesses in the subset of travelers returning from North Africa and the Middle East. [PubMed: 23552375]
58. Vassallo DJ. The corps disease: brucellosis and its historical association with the Royal Army Medical Corps. *J R Army Med Corps.* 1992; 138:140–150. [PubMed: 1453384]
59. Swai ES, Schoonman L. Human brucellosis: seroprevalence and risk factors related to high risk occupational groups in Tanga Municipality, Tanzania. *Zoonoses Public Health.* 2009; 56:183–187. [PubMed: 18811674]

60. Ramos TR, Pinheiro JW Junior, Moura Sobrinho PA, et al. Epidemiological aspects of an infection by *Brucella abortus* in risk occupational groups in the microregion of Araguaina, Tocantins. *Braz J Infect Dis.* 2008; 12:133–138. [PubMed: 18641850]
61. John K, Fitzpatrick J, French N, et al. Quantifying risk factors for human brucellosis in rural northern Tanzania. *PLoS One.* 2010; 5:e9968. [PubMed: 20376363]
62. Earhart K, Vafakolov S, Yarmohamedova N, et al. Risk factors for brucellosis in Samarqand Oblast, Uzbekistan. *Int J Infect Dis.* 2009; 13:749–753. [PubMed: 19457689]
63. Kozukeev TB, Ajeilat S, Maes E, Favorov M. Risk factors for brucellosis: Leylek and Kadamjay districts, Batken Oblast, Kyrgyzstan, January–November, 2003. *MMWR Morb Mortal Wkly Rep.* 2006; 55 (Suppl 1):31–34. [PubMed: 16645580]
64. Makita K, Fevre EM, Waiswa C, et al. Spatial epidemiology of hospital-diagnosed brucellosis in Kampala, Uganda. *Int J Health Geogr.* 2011; 10:52. [PubMed: 21962176]
65. Makita K, Fevre EM, Waiswa C, et al. How human brucellosis incidence in urban Kampala can be reduced most efficiently? A stochastic risk assessment of informally-marketed milk. *PLoS One.* 2010; 5:e14188. [PubMed: 21152072]
66. Akbayram S, Dogan M, Akgun C, et al. An analysis of children with brucellosis associated with pancytopenia. *Pediatr Hematol Oncol.* 2011; 28:203–208. [PubMed: 21381870]
67. Citak EC, Citak FE, Tanyeri B, Arman D. Hematologic manifestations of brucellosis in children: 5 years experience of an anatolian center. *J Pediatr Hematol Oncol.* 2010; 32:137–140. [PubMed: 20147850]
68. Troy SB, Rickman LS, Davis CE. Brucellosis in San Diego: epidemiology and species-related differences in acute clinical presentations. *Medicine (Baltimore).* 2005; 84:174–187. [PubMed: 15879907]
69. Mete B, Kurt C, Yilmaz MH, et al. Vertebral osteomyelitis: eight years' experience of 100 cases. *Rheumatol Int.* 2012; 32:3591–3597. [PubMed: 22095392]
70. Oztekin O, Calli C, Adibelli Z, et al. Brucellar spondylodiscitis: magnetic resonance imaging features with conventional sequences and diffusion-weighted imaging. *Radiol Med.* 2010; 115:794–803. [PubMed: 20182812]
71. Bozgeyik Z, Ozdemir H, Demirdag K, et al. Clinical and MRI findings of brucellar spondylodiscitis. *Eur J Radiol.* 2008; 67:153–158. [PubMed: 17706906]
72. Abo-shehada MN, Abu-Halaweh M. Seroprevalence of *Brucella* species among women with miscarriage in Jordan. *East Mediterr Health J.* 2011; 17:871–874. [PubMed: 22276497]
73. Karcaaltincaba D, Sencan I, Kandemir O, et al. Does brucellosis in human pregnancy increase abortion risk? Presentation of two cases and review of literature. *J Obstet Gynaecol Res.* 2010; 36:418–423. [PubMed: 20492399]
74. Colmenero JD, Reguera JM, Martos F, et al. Complications associated with *Brucella melitensis* infection: a study of 530 cases. *Medicine (Baltimore).* 1996; 75:195–211. [PubMed: 8699960]
75. Zribi M, Ammari L, Masmoudi A, et al. Clinical manifestations, complications and treatment of brucellosis: 45-patient study. *Pathol Biol (Paris).* 2009; 57:349–352. [PubMed: 18387752]
76. Kunda J, Fitzpatrick J, Kazwala R, et al. Health-seeking behaviour of human brucellosis cases in rural Tanzania. *BMC Public Health.* 2007; 7:315. [PubMed: 17980046]
77. Department of Communicable Disease and Response. WHO Recommended Surveillance Standards. 2. Geneva: WHO; 1999.
78. Araj GF. Update on laboratory diagnosis of human brucellosis. *Int J Anti-microb Agents.* 2010; 36 (Suppl 1):S12–S17.
79. Yagupsky P. Detection of brucellae in blood cultures. *J Clin Microbiol.* 1999; 37:3437–3442. [PubMed: 10523530]
80. Diaz R, Casanova A, Ariza J, Moriyon I. The Rose Bengal Test in human brucellosis: a neglected test for the diagnosis of a neglected disease. *PLoS Negl Trop Dis.* 2011; 5:e950. [PubMed: 21526218]
81. El-Fekhfakh EA, Hassanain NA, El-Folly RF, El-Hariri H. Assessment of Rose Bengal test in diagnosing Egyptian human brucellosis. *J Egypt Soc Parasitol.* 2011; 41:497–512. [PubMed: 21980786]

82. Serra J, Vinas M. Laboratory diagnosis of brucellosis in a rural endemic area in northeastern Spain. *Int Microbiol*. 2004; 7:53–58. [PubMed: 15179607]
83. Shemesh AA, Yagupsky P. Limitations of the standard agglutination test for detecting patients with *Brucella melitensis* bacteremia. *Vector Borne Zoonotic Dis (Larchmont, N Y)*. 2011; 11:1599–1601.
84. Fadeel MA, Hoffmaster AR, Shi J, et al. Comparison of four commercial IgM and IgG ELISA kits for diagnosing brucellosis. *J Med Microbiol*. 2011; 60:1767–1773. [PubMed: 21835974]
85. Centers for Disease Control and Prevention. Public health consequences of a false-positive laboratory test result for *Brucella*—Florida, Georgia, and Michigan, 2005. *MMWR Morb Mortal Wkly Rep*. 2008; 57:603–605. [PubMed: 18528317]
86. Matero P, Hemmila H, Tomaso H, et al. Rapid field detection assays for *Bacillus anthracis*, *Brucella* spp. *Francisella tularensis* and *Yersinia pestis*. *Clin Microbiol Infect*. 2011; 17:34–43. [PubMed: 20132255]
87. Marei A, Boghdadi G, Abdel-Hamed N, et al. Laboratory diagnosis of human brucellosis in Egypt and persistence of the pathogen following treatment. *J Infect Dev Ctries*. 2011; 5:786–791. [PubMed: 22112732]
88. Mizanbayeva S, Smits HL, Zhalilova K, et al. The evaluation of a user-friendly lateral flow assay for the serodiagnosis of human brucellosis in Kazakhstan. *Diagn Microbiol Infect Dis*. 2009; 65:14–20. [PubMed: 19679230]
89. Abdoel TH, Smits HL. Rapid latex agglutination test for the serodiagnosis of human brucellosis. *Diagn Microbiol and Infect Dis*. 2007; 57:123–128. [PubMed: 17258083]
90. Colmenero JD, Clavijo E, Morata P, et al. Quantitative real-time polymerase chain reaction improves conventional microbiological diagnosis in an outbreak of brucellosis due to ingestion of unpasteurized goat cheese. *Diagn Microbiol Infect Dis*. 2011; 71:294–296. [PubMed: 21855249]
91. Kumar S, Tuteja U, Sarika K, et al. Rapid multiplex PCR assay for the simultaneous detection of the *Brucella* genus, *B. abortus*, *B. melitensis*, and *B. suis*. *J Microbiol Biotechnol*. 2011; 21:89–92. [PubMed: 21301197]
92. Winchell JM, Wolff BJ, Tiller R, et al. Rapid identification and discrimination of *Brucella* isolates by use of real-time PCR and high-resolution melt analysis. *J Clin Microbiol*. 2010; 48:697–702. [PubMed: 20053863]
93. Queipo-Ortuno MI, Colmenero JD, Bermudez P, et al. Rapid differential diagnosis between extrapulmonary tuberculosis and focal complications of brucellosis using a multiplex real-time PCR assay. *PLoS One*. 2009; 4:e4526. [PubMed: 19225565]
94. Yousefi-Nooraie R, Mortaz-Hejri S, Mehrani M, Sadeghipour P. Antibiotics for treating human brucellosis. *Cochrane Database Syst Rev*. 2012; 10:CD007179. This systematic review provides the reader a quick avenue to the key therapeutic trials that have shaped brucellosis treatment recommendations. [PubMed: 23076931]
95. Skalsky K, Yahav D, Bishara J, et al. Treatment of human brucellosis: systematic review and meta-analysis of randomised controlled trials. *BMJ*. 2008; 336:701–704. [PubMed: 18321957]
96. Hasanjani Roushan MR, Mohraz M, Hajiahmadi M, et al. Efficacy of gentamicin plus doxycycline versus streptomycin plus doxycycline in the treatment of brucellosis in humans. *Clin Infect Dis*. 2006; 42:1075–1080. [PubMed: 16575723]
97. Hashemi SH, Gachkar L, Keramat F, et al. Comparison of doxycycline-streptomycin, doxycycline-rifampin, and ofloxacin-rifampin in the treatment of brucellosis: a randomized clinical trial. *Int J Infect Dis*. 2012; 16:e247–e251. [PubMed: 22296864]
98. Keramat F, Ranjbar M, Mamani M, et al. A comparative trial of three therapeutic regimens: ciprofloxacin-rifampin, ciprofloxacin-doxycycline and doxycycline-rifampin in the treatment of brucellosis. *Trop Doct*. 2009; 39:207–210. [PubMed: 19762571]
99. Ranjbar M, Keramat F, Mamani M, et al. Comparison between doxycycline-rifampin-amikacin and doxycycline-rifampin regimens in the treatment of brucellosis. *Int J Infect Dis*. 2007; 11:152–156. [PubMed: 16798042]
100. Roushan MR, Amiri MJ, Janmohammadi N, et al. Comparison of the efficacy of gentamicin for 5 days plus doxycycline for 8 weeks versus streptomycin for 2 weeks plus doxycycline for 45 days

- in the treatment of human brucellosis: a randomized clinical trial. *J Antimicrob Chemother.* 2010; 65:1028–1035. [PubMed: 20215128]
101. Solis Garcia del Pozo J, Solera J. Systematic review and meta-analysis of randomized clinical trials in the treatment of human brucellosis. *PLoS One.* 2012; 7:e32090. [PubMed: 22393379]
 102. Ariza J, Bosilkovski M, Cascio A, et al. Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations. *PLoS Med.* 2007; 4:e317. [PubMed: 18162038]
 103. Bayram Y, Korkoca H, Aypak C, et al. Antimicrobial susceptibilities of *Brucella* isolates from various clinical specimens. *Int J Med Sci.* 2011; 8:198–202. [PubMed: 21448305]
 104. Maves RC, Castillo R, Guillen A, et al. Antimicrobial susceptibility of *Brucella melitensis* isolates in Peru. *Antimicrob Agents Chemother.* 2011; 55:1279–1281. [PubMed: 21199926]
 105. Sayan M, Kilic S, Uyanik MH. Epidemiological survey of rifampicin resistance in clinic isolates of *Brucella melitensis* obtained from all regions of Turkey. *J Infect Chemother.* 2012; 18:41–46. This study found no rifampin resistance among 94 *B. melitensis* clinical isolates. [PubMed: 21826587]
 106. Sayan M, Yumuk Z, Dundar D, et al. Rifampicin resistance phenotyping of *Brucella melitensis* by *rpoB* gene analysis in clinical isolates. *J Chemother.* 2008; 20:431–435. [PubMed: 18676221]
 107. Valdezate S, Navarro A, Medina-Pascual MJ, et al. Molecular screening for rifampicin and fluoroquinolone resistance in a clinical population of *Brucella melitensis*. *J Antimicrob Chemother.* 2010; 65:51–53. [PubMed: 19861338]
 108. Zinsstag J, Schelling E, Roth F, et al. Human benefits of animal interventions for zoonosis control. *Emerg Infect Dis.* 2007; 13:527–531. [PubMed: 17553265]
 109. Perkins SD, Smither SJ, Atkins HS. Towards a *Brucella* vaccine for humans. *FEMS Microbiol Rev.* 2010; 34:379–394. [PubMed: 20180858]
 110. Godfroid J, Al Dahouk S, Pappas G, et al. A ‘One Health’ surveillance and control of brucellosis in developing countries: moving away from improvisation. *Comp Immunol Microbiol Infect Dis.* 2013; 36:241–248. This work gives excellent guidance on concepts for animal reservoir dynamics to ensure that control efforts are targeted at the appropriate host population and at the appropriate transmission routes. [PubMed: 23044181]
 111. Godfroid J, Scholz HC, Barbier T, et al. Brucellosis at the animal/ecosystem/ human interface at the beginning of the 21st century. *Prev Vet Med.* 2011; 102:118–131. [PubMed: 21571380]
 112. McDermott JJ, Arimi SM. Brucellosis in sub-Saharan Africa: epidemiology, control and impact. *Vet Microbiol.* 2002; 90:111–134. [PubMed: 12414138]
 113. Marcotty T, Matthys F, Godfroid J, et al. Zoonotic tuberculosis and brucellosis in Africa: neglected zoonoses or minor public-health issues? The outcomes of a multidisciplinary workshop. *Ann Trop Med Parasitol.* 2009; 103:401–411. [PubMed: 19583911]
 114. Renukaradhya GJ, Isloor S, Rajasekhar M. Epidemiology, zoonotic aspects, vaccination and control/eradication of brucellosis in India. *Vet Microbiol.* 2002; 90:183–195. [PubMed: 12414143]
 115. Ward D, Jackson R, Karomatullo H, et al. Brucellosis control in Tajikistan using Rev 1 vaccine: change in seroprevalence in small ruminants from 2004 to 2009. *Vet Rec.* 2012; 170:100. This study reports a large-scale vaccine intervention in Tajikistan demonstrating decreased prevalence of brucellosis in small ruminant herds. [PubMed: 22121155]
 116. Haydon DT, Cleaveland S, Taylor LH, Laurenson MK. Identifying reservoirs of infection: a conceptual and practical challenge. *Emerg Infect Dis.* 2002; 8:1468–1473. [PubMed: 12498665]

KEY POINTS

- Brucellosis is a neglected, underrecognized zoonotic infection in the developing world that can present as an acute undifferentiated fever syndrome and progress to chronic, focal forms.
- Brucellosis requires a unique treatment regimen not likely to be addressed by empiric regimens for other causes of acute undifferentiated fever syndromes: 6 weeks of doxycycline with a parenteral aminoglycoside administered concurrently during the first 1–2 weeks of therapy is the most effective regimen.
- The effects of brucellosis in human populations include the direct, sometimes debilitating morbidity from infection as well as substantial socioeconomic impact mediated by abortion and reduced productivity among livestock.
- Control of livestock brucellosis is the most effective means of reducing human brucellosis burden, but more research, including cost-effectiveness studies, is needed to demonstrate optimal control strategies in the developing world.

Table 1

Treatment of human brucellosis

| | Antimicrobial agent | Comments |
|----------------------|--|---|
| Recommended regimens | Doxycycline 100 mg p.o. b.i.d. for 6 weeks plus (Gentamicin 5 mg/kg/day i.v./i.m. daily for 7–10 days) or (streptomycin 1 g i.m. daily for 14–21 days) | Although randomized studies monitored for adverse reactions to aminoglycosides, aminoglycoside serum levels were not performed in most studies and rates of ototoxicity and nephrotoxicity were low Pediatric dosing: doxycycline relatively contraindicated, gentamicin 5 mg/kg i.m./i.v. daily, streptomycin 20 mg/kg i.m. daily |
| | Doxycycline 100 mg p.o. b.i.d. for 6 weeks plus Rifampin 600–900 mg p.o. daily for 6 weeks | Higher rates of composite (relapse or treatment failure) as well as higher rates of adverse events compared to doxycycline and an aminoglycoside Pediatric dosing: rifampin 15 mg/kg p.o. daily |
| Alternative agents | Ciprofloxacin 500 mg p.o. b.i.d. for 6 weeks or Ofloxacin 200–400 mg p.o. b.i.d. | |
| | Trimethoprim–sulfamethoxazole (160 mg/800 mg p.o. b.i.d. or 8 mg/kg/day trimethoprim component p.o. divided every 8 hours) for 6–8 weeks | Recommended for treatment of childhood brucellosis in conjunction with an aminoglycoside or rifampin Pediatric dosing: 8 mg/kg b.i.d. trimethoprim component |

b.i.d., twice daily; i.m., intramuscularly; i.v., intravenously; p.o., by mouth. Data from [1,94^{***}].